Illumina

BRUSSELS (Reuters) - Europe's top court on Tuesday backed U.S. gene sequencing company Illumina's fight against EU antitrust investigations into its $7.1 billion bid for cancer diagnostic test maker Grail. "The European Court of Justice…

© Reuters. FILE PHOTO: A sign at the front entrance to the global headquarters of Illumina is pictured in San Diego, California, U.S., November 28, 2022. REUTERS/Mike Blake/File Photo (Reuters) -Illumina said on Sunday that it would…

Sundry Photography/iStock Editorial via Getty Images Illumina's (NASDAQ:ILMN) planned $7.1 billion purchase of cancer test developer Grail was sent back to the Federal Trade Commission by a U.S. appeals court, who still determined that…

(Reuters) - U.S. genetic testing Illumina on Thursday trimmed its annual profit forecast for the second straight quarter, hurt by weakness in demand for its sequencing instruments, consumables and services.Shares of the San Diego,…

monsitj Bernstein is bullish on medtech stocks Thermo Fisher, Guardant Health, Revvity and PacBio, but sees further downside for Illumina, according to a new industry note. The investment firm kicked off coverage of the US life science…

Get free Illumina Inc updatesWe will send you a file myFT Daily Digest Rounding email to the latest Illumina CorporationNews every morning. The European Union has imposed a record fine on Illumina after the world's largest…

Sundry Photography/iStock Editorial via Getty Images illumina (Nasdaq: ILMN) a record fine from the European Union as early as next week after completing its purchase of cancer screening company Grail without the approval of the…

© Reuters. FILE PHOTO: A sign at the front entrance of Illumina's global headquarters in San Diego, California, US, November 28, 2022. REUTERS/Mike Blake/File Photo (Reuters) - The maker of genetic sequencing equipment said Monday…

© Reuters. FILE PHOTO: A sign at the front entrance of Illumina's global headquarters in San Diego, California, US, November 28, 2022. REUTERS/Mike Blake (Reuters) - The chief executive of Illumina (NASDAQ: NASDAQ) resigned on…

Illumina CEO Francis D'Souza has resigned after a painful proxy battle with activist investor Carl Icahn over the future of the world's largest gene-sequencing company.Illumina said on Sunday that the company's board of directors had…